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ABSTRACT
ObjeCtive
To test the optimal antithrombotic regimen in patients 
with acute coronary syndrome.
Design
andomised controlled trial.
setting
Patients with acute coronary syndrome with and 
without ST segment elevation in 78 centres in Italy, the 
Netherlands, Spain, and Sweden.
PartiCiPants
7213 patients with acute coronary syndrome and 
planned percutaneous coronary intervention: 
4010 with ST segment elevation and 3203 without 
ST segment elevation. The primary study results 
in the overall population have been reported 
previously.
interventiOns
Patients were randomly assigned, in an open label 
fashion, to one of two regimens: bivalirudin with 
glycoprotein IIb/IIIa inhibitors restricted to procedural 
complications or heparin with or without glycoprotein 
IIb/IIIa inhibitors.
Main OutCOMe Measures
Primary endpoints were the occurrence of major 
adverse cardiovascular events, defined as death, 
myocardial infarction or stroke; and net adverse 
clinical events, defined as major bleeding or major 
adverse cardiovascular events, both assessed at 30 
days. Analyses were performed by the principle of 
intention to treat.
results
Use of a glycoprotein IIb/IIIa inhibitor in patients 
assigned to heparin was planned at baseline in 30.7% 
of patients with ST segment elevation, in 10.9% 
without ST segment elevation, and in no patients 
assigned to bivalirudin. In patients with ST segment 
elevation, major adverse cardiovascular events 
occurred in 118 (5.9%) assigned to bivalirudin and 129 
(6.5%) assigned to heparin (rate ratio 0.90, 95% 
confidence interval 0.70 to 1.16; P=0.43), whereas net 
adverse clinical events occurred in 139 (7.0%) patients 
assigned to bivalirudin and 163 (8.2%) assigned to 
heparin (0.84, 0.67 to 1.05; P=0.13). In patients 
without ST segment elevation, major adverse 
cardiovascular events occurred in 253 (15.9%) 
assigned to bivalirudin and 262 (16.4%) assigned to 
heparin (0.97, 0.80 to 1.17; P=0.74), whereas net 
adverse clinical events occurred in 262 (16.5%) 
patients assigned to bivalirudin and 281 (17.6%) 
assigned to heparin (0.93, 0.77 to 1.12; P=0.43).
COnClusiOns
A bivalirudin monotherapy strategy compared with 
heparin with or without glycoprotein IIb/IIIa inhibitors, 
did not result in reduced major adverse cardiovascular 
events or net adverse clinical events in patients with or 
without ST segment elevation.
trial registratiOn
ClinicalTrials.gov NCT01433627.
Introduction
In patients with acute coronary syndromes managed 
invasively with coronary angiography and revasculari-
sation the optimal strategy for preventing coronary 
thrombosis and ischaemia, while limiting bleeding, is 
uncertain. Two commonly adopted regimens consist of 
unfractionated heparin, an indirect thrombin inhibitor, 
with or without concomitant use of a glycoprotein IIb/
IIIa inhibitor in case of percutaneous coronary inter-
vention; and bivalirudin, a direct thrombin inhibitor, 
with the use of glycoprotein IIb/IIIa inhibitors restricted 
to periprocedural thrombotic complications. This latter 
strategy has been associated with reduced bleeding, an 
outcome extensively associated with mortality. Previ-
ous moderately sized studies in patients with acute cor-
onary syndrome provided conflicting results on the 
WhAT IS AlReAdy knoWn on ThIS TopIC
The optimal antithrombotic regimen in patients with acute coronary syndrome with 
and without ST segment elevation is not yet defined
WhAT ThIS STudy AddS
A regimen of bivalirudin alone compared with unfractionated heparin with 
provisional use of glycoprotein IIb/IIIa inhibitors in patients with acute coronary 
syndrome with or without ST segment elevation, did not result in reduced major 
adverse cardiovascular events or net adverse clinical events
A strategy of bivalirudin monotherapy was associated with reduced bleeding 
compared with heparin with provisional use of glycoprotein IIb/IIIa inhibitors
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comparative efficacy and safety of these two 
 strategies.1-4  We therefore designed the Minimizing 
Adverse Haemorrhagic Events by Transradial Access 
Site and Systemic Implementation of Angiox (MATRIX) 
phase 3 programme in patients with acute coronary 
syndrome managed invasively via the radial or femoral 
route.5  In this large, randomised controlled trial we 
assessed whether bivalirudin is superior to unfraction-
ated heparin with or without concomitant use of glyco-
protein IIb/IIIa inhibitors. Bivalirudin did not 
significantly reduce the two coprimary endpoints of 
major adverse cardiovascular events and net adverse 
clinical events in the overall acute coronary syndrome 
population of 7213 patients.6
However, the use of these two strategies in clinical 
practice,7  as well as the profile of efficacy on ischaemic 
and thrombotic complications (eg, stent thrombosis), 
and safety in terms of bleeding8 might differ depending 
on the type of acute coronary syndrome at presentation—
that is, with or without persistent ST segment elevation.
We present the results of prespecified, randomised 
comparisons of bivalirudin with heparin in two MATRIX 
subpopulations with acute coronary syndrome: 4010 
patients presenting with persistent ST elevation and 
3203 patients presenting without persistent ST segment 
elevation for whom percutaneous coronary interven-
tion was planned at the time of coronary angiography.
Methods
study design
MATRIX was a programme of three independent ran-
domised controlled trials in an all comers population 
with acute coronary syndrome, with or without per-
sistent ST segment elevation. The first trial, MATRIX 
Access Site, compared transradial access with trans-
femoral access in 8404 patients with acute coronary 
syndrome, 4010 (47.7%) with ST segment elevation and 
4394 (52.3%) without ST segment elevation.9  The sec-
ond trial, MATRIX Antithrombin, was a randomised 
comparison of two antithrombotic strategies: bivaliru-
din with use of glycoprotein IIb/IIIa inhibitors restricted 
to angiographic complications (eg, giant thrombus) 
compared with unfractionated heparin with use of gly-
coprotein IIb/IIIa inhibitors left to the discretion of the 
investigator.6  These strategies were compared in the 
overall population with ST segment elevation (n=4010) 
and in patients without ST segment elevation for whom 
percutaneous coronary intervention was planned 
(n=3203, 72.9% of the overall population without ST 
segment elevation). The third trial, MATRIX Treatment 
Duration, was a randomised comparison within 
patients assigned to bivalirudin, comparing extended 
bivalirudin administration after percutaneous coronary 
intervention with short term administration during per-
cutaneous coronary intervention only.6
Participants
Patients with ST segment elevation were eligible: 1) if 
they experienced more than 20 minutes of ischaemic 
symptoms with ST segment elevation of ≥1 mm in two or 
more contiguous electrocardiogram leads, or with a 
new left bundle branch block, or 2) in case of ST seg-
ment depression of ≥1 mm in two or more of leads V1-V3 
with a positive terminal T wave if presented within 12 
hours of symptom onset, or 3) if there was evidence of 
continuing ischaemia or previous fibrinolytic treatment 
between 12 and 24 hours after symptom onset. We use 
the term acute coronary syndrome with ST segment ele-
vation instead of ST elevation myocardial infarction to 
recognise the possibility of an aborted myocardial 
infarction in patients presenting with acute coronary 
syndrome and persistent ST segment elevation.10
Patients without ST segment elevation were eligible if 
they had a history consistent with new or worsening 
cardiac ischaemia, occurring at rest or with minimal 
activity within seven days before randomisation, and 
fulfilled at least two high risk criteria among the follow-
ing: age 60 years or older, increase in cardiac biomark-
ers, or electrocardiographic changes consistent with 
cardiac ischaemia; consideration as a possible candi-
date for percutaneous coronary intervention after com-
pletion of coronary angiography.
Key exclusion criteria (for patients both with and 
without ST segment elevation) were treatment with low 
molecular weight heparins within the past six hours; 
treatment with any glycoprotein IIb/IIIa inhibitor in the 
previous three days; contraindications to angiography, 
including but not limited to severe peripheral vascular 
disease; and presumed life expectancy of less than 30 
days. Detailed inclusion and exclusion criteria have 
been published elsewhere and are listed in the 
 appendix.1 2 All patients gave written informed consent.
randomisation
Using a computer generated random sequence, we ran-
domised patients in a 1:1 ratio to receive the bivalirudin 
strategy or unfractionated heparin strategy, with a ran-
dom block size stratified by type of acute coronary syn-
drome—ie, with ST segment elevation versus without 
ST segment elevation—intended or ongoing use of P2Y12 
inhibitor (clopidogrel versus ticagrelor or prasugrel), 
and study site.
Owing to the high likelihood of patients with ST seg-
ment elevation receiving percutaneous coronary inter-
vention, we simultaneously randomised all patients 
with ST segment elevation to the comparisons of access 
site, antithrombin, and treatment duration (one step 
randomisation process). To account for the patients 
without ST segment elevation who would not undergo 
percutaneous coronary intervention after angiography 
and to minimise the risk that this might unbalance the 
distribution of patients for the tested drug options, we 
also allowed randomisation to the antithrombin com-
parison (either bivalirudin or heparin strategy) after 
coronary angiography and the decision had been taken 
to proceed to percutaneous coronary intervention. 
Hence, a two step randomisation process (randomisa-
tion to access site before angiography followed by ran-
domisation to antithrombin, including randomisation 
to treatment duration, only in those undergoing percu-
taneous coronary intervention) was selected in most of 
the patients without ST segment elevation.  Additionally, 
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randomisation of patients without ST segment eleva-
tion for which a two step randomisation was selected by 
the investigator was stratified by the actual treatment 
strategy (ie, coronary angiography only, not followed by 
percutaneous coronary intervention; or coronary angi-
ography followed by planned percutaneous coronary 
intervention).
Procedures
We administered all interventions in an open label fash-
ion. Bivalirudin was given according to the product 
labelling, with a bolus of 0.75 mg/kg body weight fol-
lowed immediately by an infusion of 1.75 mg/kg body 
weight hourly until completion of percutaneous coro-
nary intervention. Bivalirudin was then stopped at the 
end of percutaneous coronary intervention, or pro-
longed in accordance with the subsequent random 
assignment. In patients allocated to prolonged treat-
ment, bivalirudin could be administered for up to four 
hours at the full dose or at a reduced dose of 0.25/mg/kg 
body weight hourly for at least six hours, at the discre-
tion of the treating doctors. Heparin was dosed at 
70-100 units/kg body weight in patients not receiving 
glycoprotein IIb/IIIa inhibitors and at 50-70 units/kg 
body weight in patients receiving glycoprotein IIb/IIIa 
inhibitors. Subsequent heparin dosing based on acti-
vated clotting time was again left to the discretion of the 
investigator. A glycoprotein IIb/IIIa inhibitor could be 
administered before percutaneous coronary interven-
tion in patients in the heparin group based on investiga-
tor’s judgment, but in the bivalirudin group it was 
restricted only to patients with thrombotic complica-
tions at the time of percutaneous coronary intervention, 
including no reflow or giant thrombus. Use of other 
drugs was allowed as per guidelines. Clinical follow-up 
was performed at 30 days.
Outcomes
The MATRIX Antithrombin trial had two coprimary out-
comes, identical for patients with and without ST seg-
ment elevation: major adverse cardiovascular events 
and net adverse clinical events, both assessed at 30 
days. Considering the extensive association of bleeding 
with mortality and that both experimental treatments 
tested in MATRIX (radial access and bivalirudin mono-
therapy) were expected to reduce bleeding, we included 
net adverse clinical events as the coprimary endpoint.
We defined major adverse cardiovascular events as 
the composite of all cause mortality, myocardial infarc-
tion, or stroke; and net adverse clinical events as the 
composite of major bleeding unrelated to coronary 
artery bypass graft (Bleeding Academic Research Con-
sortium type 3 or 5, also see supplementary file),11  or 
major adverse cardiovascular events. Secondary out-
comes included each component of the composite out-
comes, cardiovascular mortality, and stent thrombosis. 
Bleeding was also assessed and adjudicated on the 
basis of the Thrombolysis In Myocardial Infarction 
(TIMI) and Global Utilization of Streptokinase and Tis-
sue Plasminogen Activator for Occluded Coronary 
Arteries (GUSTO) scales.12
An independent clinical events committee, blinded 
to randomised treatment allocation, adjudicated all 
suspected events according to prespecified definitions. 
The appendix details the definitions for endpoints adju-
dicated by the clinical events committee.
statistical analysis
The overall MATRIX Antithrombin trial was designed as 
a superiority study on two coprimary outcomes: major 
adverse cardiovascular events and net adverse clinical 
events. We expected that the incidence of 30 day major 
adverse cardiovascular events (death, myocardial 
infarction, or stroke) on an intention to treat basis to be 
4.2% in the bivalirudin group and 6.0% in the unfrac-
tionated heparin group (relative risk 0.70). With an α 
error set at 2.5% to correct for the two coprimary end-
points, we considered that a sample size of 6800 ran-
domised patients or 3400 patients in each group would 
provide 85% power. For 30 day net adverse clinical 
events (death, myocardial infarction, stroke, or major 
bleeding), we expected an incidence on an intention to 
treat basis of 6.3% in the bivalirudin group and 9.0% in 
the unfractionated heparin group (relative risk 0.70). 
We determined that we would need 6800 randomised 
patients or 3400 patients in each group to provide 95% 
power with an α error set at 2.5% to correct for the two 
coprimary endpoints. Otherwise, we made no adjust-
ments for multiple comparisons when analysing sec-
ondary endpoints. We analysed the data according to 
the intention to treat principle. Outcomes were assessed 
separately for patients with and without ST segment 
elevation as time to first event using the Mantel-Cox 
method to estimate unadjusted rate ratios and corre-
sponding 95% confidence intervals.13 The proportional 
hazard assumption was verified on the basis of Schoen-
feld residuals. We used a two sided log-rank test, and 
survival curves were constructed using Kaplan-Meier 
estimates. We performed stratified analyses according 
to prespecified subgroups (centre’s annual volume of 
percutaneous coronary intervention, age, sex, body 
mass index, intended start or continuation of prasugrel 
or ticagrelor, diabetes, estimated glomerular filtration 
rate, history of peripheral vascular disease, previous 
heparin, and randomisation to access site) and esti-
mated possible effect modifications using interaction 
terms or tests for trend across ordered groups. We chose 
not to adjust for centre because the number of observa-
tions in each centre varies substantially (range 1-794). 
However, to account for the within group correlation, 
we applied a shared frailty model using Cox regression 
and observed that hazard ratios were similar to our orig-
inal Cox regression models where we did not use a 
shared frailty model. All analyses were performed using 
the statistical packages Stata 14.1 and R 3.3.0.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for recruitment, design, or implemen-
tation of the study. No patients were asked to advise on 
interpretation or writing up of results. We plan to 
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 disseminate the results of the research to all the scien-
tific community, including study participants.
Results
Patients
Between 11 October 2011 and 7 November 2014 a total of 
7213 patients were randomised in the MATRIX Anti-
thrombin trial in 78 centres in Italy, the Netherlands, 
Spain, and Sweden. Of these, 4010 (56%) qualified for 
acute coronary syndrome with ST segment elevation at 
presentation (randomised after a median of 3.1 hours 
from symptom onset) and 3203 (44%) for acute coronary 
syndrome without ST segment elevation (randomised 
after a median of 36.4 hours from symptom onset, fig 1 ). 
Of the 4010 patients with ST segment elevation, an inves-
tigator reported primary percutaneous coronary inter-
vention as the indication for angiography in 3647—that 
is, 91%. Of the remaining 363 patients with ST segment 
elevation (9.0%), 190 did not receive percutaneous coro-
nary intervention and 173 had percutaneous coronary 
intervention for an indication different from primary per-
cutaneous coronary intervention. Overall, 3442 patients 
(95.3%) in the bivalirudin group and 3474 (96.4%) in the 
heparin group actually received the allocated treatment. 
At 30 days, complete follow-up information was avail-
able for 7198 (99.8%) patients (see supplementary figures 
S1 and S2). Baseline characteristics were similar within 
qualifying groups with acute coronary syndrome, with 
burden of risk factors for atherothrombosis and comor-
bidities (including hypertension, diabetes, hypercholes-
terolaemia, previous myocardial infarction) higher in 
patients who qualified for the group without ST segment 
elevation than those who qualified for the group with ST 
segment elevation (table 1). Use of a glycoprotein IIb/IIIa 
inhibitor in patients assigned to heparin was planned at 
the time of randomisation in 30.7% of patients with ST 
segment elevation and 10.9% without ST segment eleva-
tion. In accordance with the protocol, no patient was 
assigned to bivalirudin for whom a glycoprotein IIb/IIIa 
inhibitor was planned at the time of randomisation (see 
supplementary appendix). Bailout use of a glycoprotein 
IIb/IIIa inhibitor was not significantly different between 
randomised groups in patients without ST segment ele-
vation and higher in the bivalirudin group (6.0%) com-
pared with heparin (4.3%) in the population with ST 
segment elevation (P=0.014). Administration of an oral 
P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) 
before coronary angiography was similar between 
patients in the bivalirudin group and heparin group, in 
the populations both with and without ST segment ele-
vation (see supplementary table S1). The appendix lists 
the other procedural characteristics.
Clinical outcomes
In patients with ST segment elevation, major adverse 
cardiovascular events occurred in 118 (5.9%) assigned 
to bivalirudin and 129 (6.5%) assigned to heparin (rate 
ratio 0.90, 95% confidence interval 0.70 to 1.16, P=0.43), 
whereas net adverse clinical events occurred in 139 
(7.0%) assigned to bivalirudin and 163 (8.2%) assigned 
to heparin (0.84, 0.67 to 1.05, P=0.13, fig 2  and table 2).
Femoral
(n=4207 patients)
Radial
(n=4197 patients)
Patients without ST segment elevation
managed invasively (n=4394)
Access site randomisation
(n=8404 patients)
Antithrombin randomisation
(n=7213 patients)
Patients with ST segment elevation
with planned percutaneous
coronary intervention (n=4010)
Patients with ST segment elevation
with planned percutaneous
coronary intervention (n=4010)
Patients without ST segment elevation
without planned percutaneous
coronary intervention (n=1191; 27.1%)
Patients without ST segment elevation
with planned percutaneous
coronary intervention (n=3203; 72.9%)
Coronary angiography
R 1:1
Heparin with or
without glycoprotein
IIb/IIIa inhibitors
(n=3603 patients)
Bivalirudin
(n=3610 patients)
R 1:1
R 1:1
Bivalirudin long infusionBivalirudin short infusion
Fig 1 | Flow of study participants 
table 1 | baseline characteristics of participants with acute coronary syndrome with and 
without st segment elevation. values are numbers (percentages) unless stated otherwise
Characteristics
With st segment elevation Without st segment elevation
bivalirudin  
(n=2012)
unfractionated 
heparin (n=1998)
bivalirudin 
(n=1598)
unfractionated 
heparin (n=1605)
Mean (SD) age (years) 63.9 (12.2) 63.9 (12.0) 67.4 (11.2) 67.3 (11.4)
Age ≥75 years 445 (22.1) 423 (21.2) 461 (28.8) 481 (30.0)
Male sex 1549 (77.0) 1544 (77.3) 1182 (74.0) 1220 (76.0)
Mean (SD) weight (kg) 77.8 (13.5) 77.4 (14.0) 77.7 (14.0) 77.4 (13.7)
Mean (SD) body mass index 27.1 (4.1) 26.9 (4.1) 27.3 (4.3) 27.2 (4.1)
Diabetes mellitus 363 (18.0) 355 (17.8) 452 (28.3) 431 (26.9)
Insulin dependent 73 (3.6) 79 (4.0) 123 (7.7) 108 (6.7)
Current smoker 820 (40.8) 815 (40.8) 487 (30.5) 487 (30.3)
Hypercholesterolaemia 783 (38.9) 785 (39.3) 813 (50.9) 773 (48.2)
Hypertension 1150 (57.2) 1084 (54.3) 1114 (69.7) 1138 (70.9)
Family history of CAD 561 (27.9) 563 (28.2) 430 (26.9) 429 (26.7)
Previous MI 188 (9.3) 196 (9.8) 342 (21.4) 305 (19.0)
Previous PCI 200 (9.9) 186 (9.3) 336 (21.0) 318 (19.8)
Previous CABG 29 (1.4) 23 (1.2) 98 (6.1) 72 (4.5)
Previous TIA or stroke 88 (4.4) 84 (4.2) 93 (5.8) 101 (6.3)
Peripheral vascular disease 106 (5.3) 123 (6.2) 190 (11.9) 161 (10.0)
COPD 100 (5.0) 85 (4.3) 116 (7.3) 135 (8.4)
History of renal failure 21 (1.0) 24 (1.2) 27 (1.7) 23 (1.4)
Dialysis 3 (0.1) 0 (0.0) 2 (0.1) 2 (0.1)
Clinical presentation
Cardiac arrest 67 (3.3) 72 (3.6) 13 (0.8) 11 (0.7)
Killip class:
 I 1814 (90.2) 1778 (89.0) 1461 (91.4) 1462 (91.1)
 II 129 (6.4) 157 (7.9) 95 (5.9) 107 (6.7)
 III 38 (1.9) 29 (1.5) 38 (2.4) 35 (2.2)
 IV 31 (1.5) 34 (1.7) 4 (0.3) 1 (0.1)
Previous lytic treatment 96 (4.8) 101 (5.1) 1 (0.1) 0 (0.0)
Mean (SD) SBP (mm Hg) 136.2 (26.8) 136.0 (27.1) 141.5 (24.6) 140.9 (24.0)
Mean (SD) heart rate (beats/min) 77.0 (17.3) 77.1 (17.2) 75.2 (16.3) 74.1 (15.3)
Mean (SD) LVEF (%) 48.7 (9.5) 49.1 (9.5) 52.8 (9.1) 53.2 (9.1)
Mean (SD) eGFR (mL/min) 84.4 (25.5) 85.2 (25.8) 82.6 (24.5) 83.4 (25.6)
eGFR <60 307 (15.4) 301 (15.3) 282 (17.7) 287 (17.9)
eGFR<30 20 (1.0) 25 (1.3) 18 (1.1) 15 (0.9)
CAD=coronary artery disease; MI=myocardial infarction; PCI=percutaneous coronary intervention; CABG=coronary 
artery bypass graft; TIA=transient ischaemic attack; COPD=chronic obstructive pulmonary disease; SBP=systolic 
blood pressure; LVEF=left ventricular ejection fraction; eGFR=estimated glomerular filtration rate.
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In patients without ST segment elevation, major 
adverse cardiovascular events occurred in 253 (15.9%) 
assigned to bivalirudin and 262 (16.4%) assigned to hep-
arin (0.97, 0.80 to 1.17, P=0.72), and net adverse clinical 
events occurred in 262 (16.5%) assigned to bivalirudin 
and 281 (17.6%) assigned to heparin (0.93, 0.77 to 1.12, 
P=0.43, fig 2  and table 2).
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There was no heterogeneity of treatment effect on 
mortality according to qualifying acute coronary 
syndrome at baseline (P=0.73), with bivalirudin 
associated with fewer cases of all cause death (0.68, 
0.46 to 1.01, P=0.053) and cardiovascular death (0.67, 
0.45 to 1.00, P=0.048) compared with heparin in 
patients with ST segment elevation and directionally 
similar effect in patients without ST segment eleva-
tion (0.77, 0.41 to 1.46, P=0.43, and 0.76, 0.40 to 1.47, 
P=0.42, respectively, table 2 , fig 3, and supplemen-
tary figure 3A).
Bivalirudin was associated with lower rates of BARC 3 or 
5 bleeding, both in patients with ST segment elevation 
(0.60, 0.39 to 0.92; P=0.019) and in patients without ST seg-
ment elevation (0.47, 0.26 to 0.85; P=0.011) with similar 
treatment effect using the GUSTO (moderate or severe) and 
the TIMI (major or minor) classifications of bleeding (table 
2 , fig 3, and supplementary figure 3D and appendix).
Acute stent thrombosis (definite and definite or prob-
able) were not statistically different between the groups 
with ST segment elevation (1.87, 0.83 to 4.20, P=0.13, 
and 1.88, 0.87 to 4.06, P=0.10, respectively) and without 
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ST segment elevation (0.75, 0.17 to 3.37, P=0.71, and 0.50, 
0.13 to 2.01, P=0.32, respectively), with the P value for 
interaction with qualifying acute coronary syndrome of 
0.29 for acute definite stent thrombosis and 0.09 for 
acute definite or probable stent thrombosis.
Rates of myocardial infarction were similar between 
bivalirudin and heparin in patients with and without 
ST segment elevation (1.24, 0.88 to 1.76, and 0.95, 0.78 
to 1.16, respectively, P for interaction 0.19; fig 3). Nota-
bly, 30 day event rates differed markedly between the 
two populations: 3.3% in patients with ST segment ele-
vation and 15% in those without ST segment elevation.
Randomised treatment effect on stroke was direction-
ally opposite in patients with and without ST elevation 
(P for interaction 0.0052), with bivalirudin associated 
with a lower risk of stroke compared with heparin in 
patients with ST segment elevation (0.35, 0.13 to 0.97, 
P=0.036) and a higher risk of stroke in patients without 
ST segment elevation (4.02, 0.85 to 18.95, P=0.057).
additional analyses
Figures 4-7 list the randomised treatment effect on 
major adverse cardiovascular events and net adverse 
clinical events as well as all cause mortality and bleed-
ing in patients with and without ST segment elevation 
according to prespecified subgroups (also see the sup-
plementary appendix). In patients with ST segment ele-
vation, the randomised treatment effect appeared 
consistent across most subgroups, with the exception of 
patients with an estimated glomerular filtration rate of 
less than 60 mL/min, with previous use of unfraction-
ated heparin and treated in centres with a high volume 
of percutaneous coronary intervention, where the 
bivalirudin strategy appeared more effective and safe 
than the heparin strategy. In patients with an estimated 
glomerular filtration rate of less than 60 mL/min, bivali-
rudin appeared to be associated with a reduced risk of 
death and major bleeding. Treatment effects seemed 
consistent also in patients who qualified for the group 
without ST segment elevation, with a weak nominally 
significant interaction for intended or ongoing use of 
prasugrel or ticagrelor compared with clopidogrel.
discussion
The main finding of this analysis—the largest ran-
domised comparison of bivalirudin with heparin in 
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Fig 4 | stratified analysis of coprimary composite of all cause mortality, myocardial infarction, or stroke in patients with 
acute coronary syndrome with st segment elevation. uFH=unfractionated heparin; PCi=percutaneous coronary intervention; 
bMi=body mass index
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patients with acute coronary syndrome with ST  segment 
elevation and one of the largest in patients with acute 
coronary syndrome without ST segment elevation 
treated with modern antiplatelet agents—is that a regi-
men of bivalirudin monotherapy, compared with 
unfractionated heparin with provisional glycoprotein 
IIb/IIIa inhibitors, did not result in reduced major 
adverse cardiovascular events or net adverse clinical 
events. These results are consistent with the findings 
from the overall population with acute coronary 
 syndrome.6
efficacy and safety of bivalirudin versus heparin 
strategies according to type of acute coronary 
syndrome
A strategy of bivalirudin monotherapy was associated 
with reduced bleeding compared with heparin with 
provisional use of glycoprotein IIb/IIIa inhibitors.2-4 8 
This reduction in bleeding was consistent across 
bleeding classifications (including fatal events), not 
clearly related to randomised access site (which was 
allocated in MATRIX), and of similar magnitude in 
patients with acute coronary syndrome with and 
 without ST segment elevation. These observations 
suggest that bivalirudin, if intended as a strategy to 
minimise bleeding, may be complementary to other 
strategies (eg, radial access) and could be applied with 
few restrictions to the general population with acute 
coronary syndrome, as also suggested by the associa-
tion of bivalirudin with a reduction in death and 
bleeding in patients with a low estimated glomerular 
filtration rate. In secondary analyses we observed that 
bivalirudin was associated with a reduction in all 
cause mortality as a result of lower cardiovascular dis-
ease mortality, a difference that in this analysis was 
similar between patients with and without ST segment 
elevation (P for interaction 0.72).
The excess risk of acute stent thrombosis associated 
with bivalirudin is well documented.2 3 8 We did not 
observe significant differences in the rate of acute stent 
thrombosis between randomised strategies in the 
patients with and without ST segment elevation. While 
the risk of acute stent thrombosis with bivalirudin in 
patients with ST segment elevation has been well docu-
mented (and is directionally similar in MATRIX), we 
observed no increased risk in patients without ST 
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Fig 5 | stratified analysis of coprimary composite of all cause mortality, myocardial infarction, stroke, or barC type 3 or 5 
bleeding (major and unrelated to coronary artery bypass graft) in patients with acute coronary syndrome with st segment 
elevation. uFH=unfractionated heparin; PCi=percutaneous coronary intervention; bMi=body mass index
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 segment elevation, especially if treated with potent 
P2Y12 inhibitors.
There was no clear effect of randomised treatment on 
myocardial infarction according to qualifying acute 
 coronary syndrome. The myocardial infarction compo-
nent was far more common (>4 times) in patients without 
ST segment elevation compared with patients with ST 
 segment elevation, reflecting the contribution of proce-
dural related myocardial infarction events in patients 
without ST segment elevation and a planned percutane-
ous coronary intervention. So, even when procedural 
myocardial infarctions are not accounted for (ie, patients 
with ST segment elevation), a strategy of bivalirudin 
monotherapy did not have a measurable effect on either 
coprimary endpoints, indicating a complex, competitive 
balance between thrombosis and bleeding, which may 
explain the overall neutral results.  Unexpectedly, a nom-
inally significant interaction effect between randomised 
antithrombotic strategies compared with qualifying acute 
coronary syndrome on stroke was detected. No such effect 
has previously been reported, and since it currently 
defies, to our knowledge, any plausible biological expla-
nation, we concur it might represent a spurious finding.
Finally, subgroup analysis indicates that a strategy 
of bivalirudin monotherapy with glycoprotein IIb/IIIa 
inhibitors restricted to angiographic complications 
might be useful in patients with ST segment elevation 
pretreated with heparin and with renal dysfunction. A 
benefit of bivalirudin in patients who have received 
heparin has been consistently reported.14-16  This 
effect, perhaps related to an insufficient level of anti-
coagulation provided by bivalirudin alone, suggests 
that the common practice of an immediate heparin 
bolus in patients with ST segment elevation followed 
by bivalirudin seems to be safe. The effect of bivaliru-
din in patients with renal dysfunction is less consis-
tent,17 18 but suggests that in the acute setting (where 
data on renal function are often not available) bivali-
rudin has a favourable safety profile. Finally, a benefit 
of bivalirudin compared with a heparin strategy in 
patients without ST segment elevation (but not with 
ST segment elevation) treated with novel P2Y12 inhibi-
tors might reflect a longer time required for these 
agents to reach their desired effect, a possible consid-
eration for the selection of an antithrombotic regimen 
in this population.19
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Fig 6 | stratified analysis of coprimary composite of all cause mortality, myocardial infarction, or stroke in patients with 
acute coronary syndrome without st segment elevation. uFH=unfractionated heparin; PCi=percutaneous coronary 
intervention; bMi=body mass index
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limitations of this study
We acknowledge some limitations in the current analysis. 
Although the reported subgroups were prespecified in the 
protocol, and separate statistical analyses on these sub-
groups were planned, we did not adjust for multiple com-
parisons, increasing the risk of type 1 errors. Also, the 
results for the coprimary endpoints were all negative. There-
fore, differential effects across subgroups of the randomised 
treatments, if any, must be considered hypothesis generat-
ing. Also, the study was not powered for type of acute coro-
nary syndrome at baseline. Accordingly, our ability to detect 
smaller treatment differences was limited. Finally, the study 
compared two antithrombotic strategies (with the heparin 
arm intended to reflect use of glycoprotein IIb/IIIa inhibi-
tors in clinical practice) rather than two drugs. The different 
use of glycoprotein IIb/IIIa inhibitors in the two study arms 
has thus challenged our ability to understand the efficacy 
and safety of the anticoagulants drugs alone.
Conclusions
A strategy of bivalirudin monotherapy compared with 
heparin with or without glycoprotein IIb/IIIa inhibitors 
did not result in reduced major adverse cardiovascular 
events or net adverse clinical events in patients with 
acute coronary syndrome with or without ST segment 
elevation. The choice of the anticoagulant regimen thus 
requires a careful balance between the expected risk of 
bleeding and thrombotic complications with the 
expected benefits for each patient. Further research is 
needed to better understand optimal patients, settings, 
and combinations of antithrombotic treatments, partic-
ularly in those with a high risk of early thrombotic com-
plications or a high risk of bleeding, or both.
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Fig 7 | all cause mortality, myocardial infarction, stroke, or barC type 3 or 5 bleeding (major and unrelated to coronary 
artery bypass graft) in patients with acute coronary syndrome without st segment elevation. uFH=unfractionated 
heparin; PCi=percutaneous coronary intervention; bMi=body mass index
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